Fulgent Genetics Inc

FLGT

Add to Watchlist

15.700USD

-0.490-3.03%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking

28 / 74

Overall Ranking

142 / 4482

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fulgent Genetics Inc Highlights

StrengthsRisks

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fairly Valued

The company’s latest PE is -6.55, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 18.21M shares, decreasing 7.22% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.23K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.74.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

18.500

Target Price

+14.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Fulgent Genetics Inc is 6.28, ranking 57 out of 74 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 71.14M, representing a year-over-year decrease of 3.16%, while its net profit experienced a year-over-year decrease of 115.32%.

Score

Industry at a Glance

Previous score

6.28

Change

0



Financials

7.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.96

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.51

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Fulgent Genetics Inc is 8.79, ranking 3 out of 74 in the Healthcare Providers & Services industry. Its current P/E ratio is -6.55, which is -216.18% below the recent high of 7.61 and -632.86% above the recent low of -48.02.

Score

Industry at a Glance

Previous score

8.79

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/74

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Fulgent Genetics Inc is 7.33, ranking 42 out of 74 in the Healthcare Providers & Services industry. The average price target is 35.00, with a high of 36.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.00

Change

0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Fulgent Genetics Inc is 8.78, ranking 29 out of 74 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 16.79 and the support level at 14.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.10

Change

-0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Fulgent Genetics Inc is 5.00, ranking 49 out of 74 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 64.11%, representing a quarter-over-quarter increase of 8.03%. The largest institutional shareholder is Steven Cohen, holding a total of 236.95K shares, representing 0.83% of shares outstanding, with 601.68% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hsieh (Ming)

8.87M

-0.09%

BlackRock Institutional Trust Company, N.A.

2.01M

+1.02%

Acadian Asset Management LLC

1.19M

+4.01%

Millennium Management LLC

939.38K

-36.05%

Gao (Hanlin)

931.05K

+1.34%

RTW Investments L.P.

705.03K

--

D. E. Shaw & Co., L.P.

701.30K

+23.52%

Dimensional Fund Advisors, L.P.

889.01K

-21.54%

BlackRock Financial Management, Inc.

617.43K

-6.63%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fulgent Genetics Inc is 6.80, ranking 25 out of 74 in the Healthcare Providers & Services industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Fulgent Genetics Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Fulgent Genetics Inc

FLGT

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Encompass Health Corp

EHC

8.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Concentra Group Holdings Parent Inc

CON

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Pennant Group Inc

PNTG

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Brightspring Health Services Inc

BTSG

8.34 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Hinge Health Inc

HNGE

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment